PeptideAgentAsk PeptideAgent
Comparisons/TB-500 vs Thymosin Beta-4
PEPTIDE COMPARISON

TB-500 vs Thymosin Beta-4

A marketed fragment name compared with the full-length endogenous peptide it is often confused with.

QUICK ANSWER

TB-500 vs Thymosin Beta-4: the main difference.

TB-500 and thymosin beta-4 should not be treated as synonyms. Evidence for a verified full-length or recombinant thymosin beta-4 product does not automatically validate a marketed TB-500 product.

Decision fieldTB-500 Thymosin Beta-4
EntityMarketed thymosin-beta-4-related fragment nameFull-length endogenous actin-binding peptide
Human researchVery limited direct evidenceEarly phase systemic and topical studies
Evidence transferOften borrows full-length peptide researchApplies only to the studied molecule and formulation
FDA statusNot approvedNot approved
2026 WADAProhibited at all timesProhibited at all times

SOURCES

TB-500 vs Thymosin Beta-4 sources.

WADA / 20262026 Prohibited ListWorld Anti-Doping Agency Review / 2015Thymosin beta-4 and tissue repairPubMed Human trial / 2021Phase 1 study of recombinant human thymosin beta-4PubMed Human trial / 2015Thymosin beta-4 ophthalmic solution in dry eyePubMed

RELATED QUESTIONS

Questions related to TB-500 vs Thymosin Beta-4.

What is the evidence for BPC-157 and TB-500?What is TB-500?What is Thymosin Beta-4?What is the evidence for TB-500?

RELATED COMPARISONS

BPC-157 vs TB-500BPC-157 vs Thymosin Beta-4Thymosin Alpha-1 vs Thymosin Beta-4TB-500 vs GHK-Cu